Arvin Capital Management LP Sells 6,300 Shares of IQVIA Holdings Inc. $IQV

Arvin Capital Management LP lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 14.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,600 shares of the medical research company’s stock after selling 6,300 shares during the quarter. IQVIA accounts for about 1.6% of Arvin Capital Management LP’s investment portfolio, making the stock its 20th biggest holding. Arvin Capital Management LP’s holdings in IQVIA were worth $8,701,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Eagle Rock Investment Company LLC boosted its holdings in shares of IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after buying an additional 11,657 shares during the period. EDENTREE ASSET MANAGEMENT Ltd acquired a new position in shares of IQVIA in the third quarter valued at approximately $7,368,000. AMG National Trust Bank acquired a new position in shares of IQVIA in the third quarter valued at approximately $3,713,000. Citigroup Inc. boosted its holdings in shares of IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock valued at $173,830,000 after buying an additional 475,557 shares during the period. Finally, Dana Investment Advisors Inc. lifted its position in shares of IQVIA by 18.4% in the third quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company’s stock worth $30,401,000 after purchasing an additional 24,854 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research reports. Mizuho set a $215.00 price objective on shares of IQVIA in a research report on Monday, February 23rd. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research report on Friday, March 6th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Morgan Stanley set a $225.00 price objective on shares of IQVIA in a research report on Thursday, May 7th. Finally, Truist Financial cut their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $224.13.

IQVIA Price Performance

Shares of IQV opened at $181.10 on Friday. The company has a market cap of $30.23 billion, a price-to-earnings ratio of 22.44, a PEG ratio of 1.56 and a beta of 1.21. IQVIA Holdings Inc. has a 1-year low of $153.01 and a 1-year high of $247.04. The company’s fifty day simple moving average is $173.56 and its 200 day simple moving average is $193.68. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.